Agenus | AGEN - Cash And Equivalent


Agenus reported $18.74M in Cash and Equivalent for its fiscal quarter ending in June of 2026.





Cash And Equivalent Change Date
AbbVie USD 6.57B 2.82B Jun/2026
Agenus USD 18.74M 16.26M Jun/2026
Amgen USD 13.99B 1.95B Jun/2026
AstraZeneca USD 4.89B 2.67B Jun/2026
Bristol-Myers Squibb USD 8.72B 852M Jun/2026
Celldex Therapeutics USD 47.45M 11.72M Jun/2026
CSL USD 2.16B 633M Jun/2025
Eli Lilly USD 8.95B 3.67B Jun/2026
Gilead Sciences USD 7.63B 64M Mar/2026
GlaxoSmithKline GBP 3.44B 292M Mar/2026
Glaxosmithkline GBP 3.44B 146M Mar/2026
Incyte USD 3.98B 33.45M Jun/2026
Intrexon USD 9.34M 1.77M Jun/2024
J&J USD 20.42B 1.27B Jun/2026
Jiangsu Hengrui CNY 40.53B 428.6M Mar/2026
Karyopharm Therapeutics USD 90.85M 30.31M Mar/2026
MacroGenics USD 113.91M 47.39M Jun/2026
Merck EUR 2.74B 415M Mar/2026
Merck USD 6.85B 1.52B Jun/2026
Northwest Biotherapeutics USD 4.56M 244K Sep/2025
Novartis USD 7.62B 739M Jun/2026
Novavax USD 191.46M 36.9M Jun/2026
Pfizer USD 976M 727M Jun/2026
Regeneron Pharmaceuticals USD 2.46B 506.8M Jun/2026
Rigel Pharmaceuticals USD 48.53M 4.87M Sep/2025
Sangamo BioSciences USD 38.34M 13.16M Jun/2025
Veracyte USD 299.52M 36.38M Jun/2026